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Summary CA-125 levels were assessed prior to each of the first three cycles of chemotherapy, in 81 patients
with epithelial ovarian cancer receiving first-line chemotherapy. All patients have at least 1 year's follow-up.
Thirty-nine patients (48%) have progressed clinically or have died within 1 year of treatment (treatment
'failures'). Three CA-125 indices previously shown to be of prognostic value are assessed for their ability to
pick-out these 'failures'. When the indices examined are modified to obtain a specificity for picking out failures
just exceeding 90%, the maximum sensitivity obtained was 46%. The use of CA-125 for clinical decision
making in ovarian cancer requires further investigation to determine and validate a prognostic index with
acceptable sensitivity and specificity, and to determine the clinical impact of treatment decisions made using
such an index.
Ovarian cancer is the most common malignancy of the
female genital tract. The age standardised death rate for
ovarian cancer is steadily rising whereas the mortality for
cervical cancer and endometrial cancer is falling, with that
for breast cancer remaining unchanged (Beral, 1987). Although
the use of cisplatin or carboplatin has made some impact in
the treatment ofadvanced epithelial ovarian cancer, the over-
all results remain disappointing (Neijt et al., 1987; Wiltshaw,
1985). In particular platinum-containing regimens are assoc-
iated with significant morbidity and may have an advelse
affect on the quality of life. Measurability is also a problem
in this disease. After primary debulking surgery many
patients have small volume residual disease which cannot be
measured by non-invasive means. In those cases where this
residual disease is resistant to chemotherapy progression con-
tinues unnoticed whilst ineffective chemotherapy continues to
be administered. In the absence of any new revolutionary
therapy an alternative approach is the development of a
prognosis orientated, patient adapted, treatment strategy. By
the use of prognostic variables it may be possible to predict
'treatment failures' who are unlikely to benefit from current
aggressive chemotherapy. Highly toxic and expensive therapy
would therefore be restricted to those patients predicted to
benefit.
The accepted clinicopathological factors of independent
prognostic significance in epithelial ovarian cancer include
age, International Federation of Obstetrics and Gynaecology
(FIGO) stage, the amount of residual disease after primary
surgery, performance status and histological grade (Neijt et
al., 1987; Heintz et al., 1988; Malkasian et al., 1984; Voest et
al., 1989). The tumour associated antigen CA-125 is the most
clinically useful serum tumour marker for epithelial ovarian
cancer (Bast et al., 1983; Canney et al., 1984; Cruickshank et
al., 1987). It is an antigenic determinant defined by a murine
IgGI monoclonal antibody raised against the serous ovarian
carcinoma cell line OVCA 433 (Bast et al., 1981). In advanc-
ed disease the reported sensitivity of pre-operative serum
CA-125 approaches 100% and follow-up changes in serial
CA-125 levels correlate with the clinical assessment of disease
in 93% of instances (Bast et al., 1983; Cruickshank et al.,
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1987). With regard to the potential prognostic value of CA-
125, there are a number of studies with different conclusions
(Cruickshank et al., 1987; Raju et al., 1987; Vergote et al.,
1987; Lavin et al., 1987; Alvarez et al., 1987; Parker et al.,
1988; Mobus et al., 1988; Van der Burg et al., 1988; Rustin et
al., 1989; Hawkins et al., 1989; Redman et al., 1990). These
studies however have differences in their selected populations,
prognostic endpoints and definitions of CA-125 characteris-
tics examined.
The aim of this study was to use an independent data set
to evaluate the relative clinical utility of a number of CA-125
parameters already shown to be of prognostic value in the
published literature (Van der Burg et al., 1988; Rustin et al.,
1989; Hawkins et al., 1989; Redman et al., 1990) within a
defined clinical scenario - viz at some time prior to the third
course of chemotherapy it is wished to distinguish reliably
between treatment 'failures' and treatment 'successes'. A
treatment failure is defined to be clinical progression or death
within 12 months of starting chemotherapy; a success is
taken to be a patient alive and progression free for at least 12
months. This is a definition designed for picking out candi-
dates for stopping chemotherapy, for while a patient who
dies or progresses within a year is clearly a failure the
converse is not such a persuasive definition of success.
Materials and methods
Patients
Eighty-one patients with a diagnosis of epithelial ovarian
cancer and a minimum of 1 years follow-up were used in this
study. Forty-four patients were treated in Aberdeen (54%),
32 in Glasgow (40%) and five (6%) in Dundee. Thirty-six
(41%) were treated with either single agent cisplatin or
carboplatin, 33 patients (41%) were treated with carboplatin/
chlorambucil or cisplatin/cyclophosphamide and a further 12
(15%) were treated with alkylating agents alone. All patients
had initial debulking surgery, although for one patient the
bulk of residual disease is not available; 54% of patients had
residual disease >2 cm. The median age of the patients was
59 years (range 21-78, interquartile range 50-64). Other
details of these patients are given in Table I.
CA-125 assay
CA-125 was measuired using the CIS-ELSA immunoradiometric
assay [CIS (UK) Limited, High Wycombe, Buckinghamshire
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Table I Patient characteristics
% No.
ECOGa 0 70 50
performance status 1 25 18
2 4 3
Total 100 71
FIGO stage 1 5 4
2 14 11
3 64 52
4 17 14
Total 100 81
Operationb Oophorectomy 87 58
Omentectomy 76 51
Total abdominal 66 44
hysterectomy
Outcome Success 52 42
Failure 48 39
Total 100 81
dECOG = Eastern Co-operative Oncology Group. bInformation on
operation typeisonlyavailablefor67patients, thus 87% (58/67) had an
oophorectomy. Most patients had more than one procedure.
HP12 3RD, UK] as recommended by the manufacturers. The
assay tubes were washed three times to remove any unbound
tracer before the radioactivity was counted. Specimens with a
CA-125 concentration of greater than 350kUl-1 were re-
assayed on dilution. The inter-assay coefficient ofvariation at
a concentration of 35 kU I' was 8%.
For the purpose of this paper the following definitions are
used:
CA-125:1 - CA-125 measurement up to 14 days prior to
the first cycle of chemotherapy.
CA-125:2-CA-125 measurement up to 14 days prior to
second cycle ofchemotherapy. This measurement
is made between day 10 and day 40 oftreatment.
CA-125:3 -CA-125 measurement up to 14 days prior to the
third cycle ofchemotherapy. This measurement is
made between day 40 and day 70 of treatment.
Summary details ofthe level and timing ofthe CA-125 measure-
ments are given in Table II.
Statistical analysis
Logistic regression (Cox, 1970) was used as the means of
assessing the predictive value of variables. Log transforma-
tions were taken (to the base e) of all CA-125 measurements
in order to improve the validity of the statistical methods
used. Logged scales are also used to improve the clarity of
the figures. CA-125 measurements below the detection limit
of the assay (i.e. < 7 KU 1-') have been taken to be 3.5. The
McNemar test was used to compare the sensitivities of the
prognostic indices at a fixed specificity.
Caveat
The fact that the three CA-125 measurements are available
for all the patients in this paper means that they are not
necessarily typical of the large number of patients treated
with ovarian cancer at these institutions on whom all these
measurements were not made. Some measurements are not
taken because of early clinical progression, but the main
reason is clinicians simply not requesting the assay for some
patients. How different the distribution of the various prog-
nostic indicators might be among failures and successes in
these patients is a matter for speculation. There is no obvious
reason to think that these distributions would be markedly
different from those presented in the text and the general
relevance of the results given rests on this assumption.
Results
Prognostic index I
In the paper by Rustin et al., it is suggested that the change
in CA-125 levels from before chemotherapy to 1 month later,
after one course of chemotherapy could be used to divide
patients into different prognostic groups. The best discrimin-
ation was found by splitting patients into those who showed
a greater than 7-fold decrease in CA-125 levels and those
who showed a smaller change.
The application of this criteria to our data is illustrated in
Figure 1. The data are plotted on a logged scale. The visible
separation in the plot between successes and failures is statis-
tically significant (P = 0.013 from logistic regression). The
predictive value of using a greater than 7-fold drop to pick
out successes if 74% (17/23); the predictive value ofusing less
than a 7-fold drop to pick out failures is 57% (33/58). The
sensitivity of this criteria for picking out treatment failures is
85% (33/39) and the specificity is 40% (17/42). The 7-fold
cut-off is designed to pick out successes, but its effectiveness
in doing so appears limited. Selecting a cut-off that just
achieves a specificity of 90% for picking out treatment fail-
ures ((CA-125:2/CA-125:1) >0.81 or less than a 19% drop)
results in a sensitivity of 31% (Table III).
Prognostic index 2
The paper by Redman et al. suggests that the absolute level
of CA-125 after two cycles of chemotherapy could be used to
classify patients into good and poor risk groups. A cut-off
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Figure 1 Success/failure according to the drop in CA-125 from
before the first course to before the second course of
chemotherapy.
Table II Details of CA-125 samples
No of
Min 25%ile Median 75%ile Max pats.
Pre-surgery CA-125 (KU I) <7 139 298 816 >9999 53
CA-125:1 (KUI-') <7 116 251 550 7686 81
CA-125:2 (KUI-') <7 22 62 222 3600 81
CA-125:3 (KUI-') <7 12 24 112 2700 81
Time from start of chemotherapy to - 11 -1 0 0 0 81
CA-125:1 (days)
Time from start of chemotherapy to 14 25 28 28 33 81
CA-125:2 (days)
Time from start ofchemotherapy to 40 49 55 57 63 81
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Table III Sensitivity and predictive value ofprognostic indices when specificity isjust >90%
[Specificity = 90% (38/42) for each index]
Level at which
>90% specificity is
just obtained Sensitivity Predictive value
Prognostic index 1 <19% drop 31% [15%-49%]a (12/39) 75% [41%-93%] (12/16)
Prognostic index 2 >94 46% [27%-64%] (18/39) 82% [54%-95%] (18/22)
Prognostic index 3 >- 0.009 31% [15%-49%] (12/39) 75% [41%-93%] (12/16)
aFigures in italic are 95% confidence intervals for the corresponding percentages.
value of 35 KU1' is used to separate patients into these
groups.
The performance of this means of classification on our
data is illustrated in Figure 2. Once again the CA-125 levels
of failures and successes are significantly different (P<0.0001,
from logistic regression), but using the value of 35 KU I` as
a cut-off would lead to a substantial degree of misclassifi-
cation. The predictive value of using >35 KU I-' to pick
out failures is 68% (26/38); the equivalent figure for successes
is 70% (30/43). The sensitivity of this criteria for picking out
treatment failures is 67% (26/39) and its specificity is 71%
(30/42). A better performance in terms ofpicking out failures
could be obtained by using a cut-off of 94KU/I-', giving a
sensitivity of 46% and a predictive value of 82% (Table III).
Prognostic index 3
Van der Burg et al. put forward CA-125 half-life as a mean
of picking out poor prognostic patients. CA-125 half-life c
greater than 20 days indicated a poor prognosis patient. i
similar prognostic index was suggested by Hawkins et a,
however this was developed for patients who had responde
to initial chemotherapy.
This prognostic criteria is illustrated for our data in Figurl
3. The results are presented in terms of the rate of change d
loge (CA-125) from just before the first course of chemo
therapy (CA-125:1) to just before the third course of chemo
therapy (CA-125:3)- this is log(1/2) times the reciprocal o
the half-life. Again there is a statistically significant separa
tion in this variable between the successes and the failure
(P = 0.0008, from logistic regression). The point equivalen
to a half-life of 20 days is indicated and using this to classif,
patients as successes or failures would lead to a large amoun
of misclassification. The predictive value of using this cut-of
for picking out failures is 70% (28/40); for successes tho
predictive values is 73% (30/41). The specificity of this cri
teria for failures is 71% (30/42) and its sensitivity is 720'
(28/39). Adjusting the cut-off to just obtain a specificit:
>90% (rate of change > - 0.009 or half-life >77 days
results in a corresponding sensitivity of 31% (Table III).
Comparison ofindices at afixedspecificity
When the specificity of each index is adjusted to 90% (Tabl
III) the sensitivities of each can be compared using th
McNemar test. There are no statistically significant differ
ences between the sensitivities of the indices (Prog. index 1 v.
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Figure 2 Success/failure according to CA-125 before the third
course of chemotherapy (CA-125:3).
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Figure 3 Success/failure according to the rate of change of log
(CA-125).
Prog. index 2, P=0.180; Prog. index I vs Prog. index 3,
P = 1.00; Prog. index 2 vs Prog. index 3, P = 0.180).
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This analysis of an independent group of patients with epi-
)f thelial ovarian cancer has cast doubt on the clinical utility of
- CA-125 criteria previously found to be of prognostic value
s (Van der Burg et al., 1988; Rustin et al., 1989; Hawkins et
it al., 1989; Redman et al., 1990) in the clinical scenario ~y envisaged in this paper. In our opinion the extent ofpotential
it misclassification using these CA-125 criteria limits their
ff clinical use given that the aim of discriminating poor from
e good prognostic groups is to influence treatment decisions. In
i- all three instances there was a substantial overlap between
the good and bad prognostic groups using the cut-offs sug-
:y gested. Using any of the CA-125 parameters tested with their
3) suggested cut-offs would result in aggressive chemotherapy
being changed to palliative treatment in a considerable
number of patients wrongly expected to have a poor out-
come. Modifying the cut-offs in order to just achieve a 90%
specificity for picking out treatment failures improves
le matters, although the corresponding sensitivities are low.
ie A statistically significant association between outcome and
r- all three CA-125 parameters tested was observed, confirming
is their prognostic value. However, within the context of clini-
cal decision making, statistical significance is only a mini-
mum requirement and, in this case, the more important
features are the potential for misclassification of patients.
What constitutes acceptable rates for misclassification is a
complex judgement balancing relative benefits in terms of
maximising quality of life, increasing survival and the cost of
treatment. This judgement further depends on knowledge of
the advantages and disadvantages of both continuing and
discontinuing aggressive therapy, both for treatment failures
and treatment successes; knowledge which at the moment
largely does not exist. It also depends on whether it is wished
) to select a group of good prognosis patients for whom to
maintain intensive treatment, or a group of poor prognosis
patients for whom to minimise the use of toxic chemo-
therapy. We have chosen a definition of success/failure more
suited to the latter purpose.
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The use of CA-125 for clinical decision making in epithe-
lial ovarian cancer requires further investigation, both in
determining and validating a prognostic index with accept-
able misclassification rates, and in determining the clinical
impact of treatment decisions made on the basis of such an
index.
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